<DOC>
	<DOC>NCT01362660</DOC>
	<brief_summary>This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).</brief_summary>
	<brief_title>A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth</brief_title>
	<detailed_description>This study will enroll infants with potential tanezumab exposure in utero at sites overseen by Schulman and Associates IRB This study will attempt to enroll all infants who qualify.</detailed_description>
	<criteria>Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study through direct maternal exposure; or is an infant born to a mother who is a partner of a male patient who was exposed to study drug in a tanezumab clinical study prior to or around the time of conception and/or is exposed during his partner's pregnancy. There are no exclusion criteria for this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>post-natal monitoring</keyword>
	<keyword>exposure in utero</keyword>
</DOC>